2.70
price up icon0.37%   0.01
after-market Dopo l'orario di chiusura: 2.62 -0.08 -2.96%
loading

AIM ImmunoTech Inc Borsa (AIM) Ultime notizie

pulisher
Aug 16, 2025

AIM ImmunoTech's Oncology Gambit: Can Pancreatic Cancer Breakthroughs and Financial Stability Fuel a Biotech Comeback? - AInvest

Aug 16, 2025
pulisher
Aug 16, 2025

AIM ImmunoTech reports Q2 EPS ($3.68) vs ($3.00) last year - MSN

Aug 16, 2025
pulisher
Aug 15, 2025

AIM ImmunoTech Reports Q2 Losses Amid Ongoing Trials, Revenue Down to $25k. - AInvest

Aug 15, 2025
pulisher
Aug 15, 2025

AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire

Aug 15, 2025
pulisher
Aug 15, 2025

Promising Pancreatic Cancer Treatment: AIM ImmunoTech's Ampligen Shows Strong Safety Data in Phase 2 - Stock Titan

Aug 15, 2025
pulisher
Aug 15, 2025

Webull Corporation shares rise 1.49% premarket after AIM ImmunoTech and Moleculin Biotech to present at Webull Financial Corporate Connect Webinar Series. - AInvest

Aug 15, 2025
pulisher
Aug 15, 2025

AIM ImmunoTech Reports Increased Losses Amid Ongoing Trials - TipRanks

Aug 15, 2025
pulisher
Aug 14, 2025

AIM ImmunoTech to present at Webull Financial Corporate Connect webinar. - AInvest

Aug 14, 2025
pulisher
Aug 14, 2025

AIM ImmunoTech CEO to Share Company Updates at Webull's Biotech Investment Series - Stock Titan

Aug 14, 2025
pulisher
Aug 14, 2025

AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech - GlobeNewswire

Aug 14, 2025
pulisher
Aug 14, 2025

AIM ImmunoTech Presents at Webull Financial Corporate Connect Webinar Series: Biotech/MedTech. - AInvest

Aug 14, 2025
pulisher
Aug 09, 2025

AIM ImmunoTech Announces Pricing of $8.0 Million Public Offering - 富途牛牛

Aug 09, 2025
pulisher
Aug 07, 2025

AIM ImmunoTech’s Oncology Drug Ampligen to Be Featured in - GlobeNewswire

Aug 07, 2025
pulisher
Aug 06, 2025

AIM ImmunoTech's Oncology Drug Ampligen to Be Featured in Key Pr - GuruFocus

Aug 06, 2025
pulisher
Aug 06, 2025

Breakthrough: New Cancer Drug Ampligen Delivers Promising Results in Pancreatic, Ovarian, and Breast Cancer Trials - Stock Titan

Aug 06, 2025
pulisher
Aug 06, 2025

AIM ImmunoTech’s Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025) - The Manila Times

Aug 06, 2025
pulisher
Aug 04, 2025

AIM ImmunoTech (AIM) Advances Clinical Trials and Strengthens Financial Position - GuruFocus

Aug 04, 2025
pulisher
Aug 04, 2025

AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on - GuruFocus

Aug 04, 2025
pulisher
Aug 04, 2025

AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval | AIM Stock News - GuruFocus

Aug 04, 2025
pulisher
Aug 04, 2025

AIM ImmunoTech Builds Positive Momentum and Reiterates - GlobeNewswire

Aug 04, 2025
pulisher
Aug 04, 2025

Breakthrough in Pancreatic Cancer Treatment: AIM's Ampligen-Imfinzi Combo Shows Positive Survival Data - Stock Titan

Aug 04, 2025
pulisher
Aug 04, 2025

AIM ImmunoTech highlights recent key financial milestones - TipRanks

Aug 04, 2025
pulisher
Aug 03, 2025

AIM ImmunoTech Surges Amid Key Developments, Raises $8 Million in Public Offering - AInvest

Aug 03, 2025
pulisher
Aug 01, 2025

AIM ImmunoTech Closes $8 Million Public Offering - The Globe and Mail

Aug 01, 2025
pulisher
Jul 31, 2025

Latest News - Asia Food Journal

Jul 31, 2025
pulisher
Jul 31, 2025

AIM ImmunoTech Announces Closing of $8.0 Million Public Offering - GlobeNewswire

Jul 31, 2025
pulisher
Jul 31, 2025

AIM ImmunoTech's $8.0M Capital Raise: A Strategic Move to Fuel Ampligen's Clinical Progress and Investor Value? - AInvest

Jul 31, 2025
pulisher
Jul 31, 2025

AIM ImmunoTech closes public offering, raises $8 mln. - AInvest

Jul 31, 2025
pulisher
Jul 31, 2025

AIM ImmunoTech Secures $8M Funding: New Shares at $4.00 Plus 5-Year Warrants - Stock Titan

Jul 31, 2025
pulisher
Jul 31, 2025

AIM ImmunoTech reports Ampligen combo trial data for pancreatic cancer - MSN

Jul 31, 2025
pulisher
Jul 30, 2025

Biotech Alert: Searches spiking for these stocks today - TipRanks

Jul 30, 2025
pulisher
Jul 30, 2025

AIM ImmunoTech's Stock Falls 50% Following $8M Securities Offering - AInvest

Jul 30, 2025
pulisher
Jul 29, 2025

Evaluating AIM ImmunoTech's Capital Raise: A Strategic Crossroads for Investors - AInvest

Jul 29, 2025
pulisher
Jul 29, 2025

AIM Shares Fall After Pricing of $8 Million Public Offering - MarketScreener

Jul 29, 2025
pulisher
Jul 29, 2025

Crude Oil Gains Over 1%; UnitedHealth Earnings Miss Views - Benzinga

Jul 29, 2025
pulisher
Jul 29, 2025

AIM ImmunoTech stock plunges after pricing $8 million public offering By Investing.com - Investing.com Australia

Jul 29, 2025
pulisher
Jul 29, 2025

AIM ImmunoTech stock plunges after pricing $8 million public offering - Investing.com

Jul 29, 2025
pulisher
Jul 29, 2025

US Stocks Mixed; Procter & Gamble Posts Upbeat Earnings - Benzinga

Jul 29, 2025
pulisher
Jul 29, 2025

AIM ImmunoTech Stock Dives 50% After Priced Public Offering - AInvest

Jul 29, 2025
pulisher
Jul 29, 2025

Why Is AIM ImmunoTech Stock (AIM) Down 50% Today? - TipRanks

Jul 29, 2025
pulisher
Jul 29, 2025

AIM ImmunoTech prices $8 million public offering at $4.00 per share - Investing.com

Jul 29, 2025
pulisher
Jul 29, 2025

AIM ImmunoTech Plunges 51.11% Amid Market Volatility - AInvest

Jul 29, 2025
pulisher
Jul 29, 2025

AIM ImmunoTech prices 2M shares at $4.00 in public offering - TipRanks

Jul 29, 2025
pulisher
Jul 29, 2025

AIM ImmunoTech Announces $8 Million Public Offering at $4 per Share with Accompanying Warrants. - AInvest

Jul 29, 2025
pulisher
Jul 29, 2025

AIM ImmunoTech Secures Fresh Capital: $8M Offering Includes Dual Warrant Structure at $4.00 - Stock Titan

Jul 29, 2025
pulisher
Jul 29, 2025

AIM ImmunoTech Inc Plunges 38.33% Amid Trading Halt - AInvest

Jul 29, 2025
pulisher
Jul 29, 2025

AIM ImmunoTech Stock Plunges 40.97% on Volatility - AInvest

Jul 29, 2025
pulisher
Jul 29, 2025

Why Celestica Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga

Jul 29, 2025
pulisher
Jul 29, 2025

AIM ImmunoTech Plunges 27.08% Amid Volatility Concerns - AInvest

Jul 29, 2025
pulisher
Jul 29, 2025

AIM ImmunoTech Reports Positive Mid-year Safety and - GlobeNewswire

Jul 29, 2025
pulisher
Jul 28, 2025

AIM ImmunoTech Inc. Trading Resumes: Enhanced Tools and Expert Analysis Available for Investors - AInvest

Jul 28, 2025
pulisher
Jul 28, 2025

Crude Oil Gains 2%; CEA Industries Shares Spike Higher - Benzinga

Jul 28, 2025
pulisher
Jul 28, 2025

Why Is Micro-Cap AIM ImmunoTech Stock Surging? - Benzinga

Jul 28, 2025
$24.65
price up icon 0.94%
$85.04
price down icon 1.72%
$26.20
price up icon 0.73%
$110.88
price up icon 0.10%
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
Capitalizzazione:     |  Volume (24 ore):